Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Accretive Health, Inc.    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Accretive Health, Inc. : Accretive Health Reports Inducement Grant under NYSE Rule 303A.08

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2013 | 01:05pm CEST

Accretive Health, Inc. (NYSE: AH) today announced that pursuant to the employment agreement entered into with Stephen Schuckenbrock on April 2, 2013, the company granted to Mr. Schuckenbrock on April 3, 2013 a non-qualified stock option under the New York Stock Exchange inducement grant exception. The inducement grant was approved by the company's Board of Directors on April 1, 2013 and is being made as an inducement material to Mr. Schuckenbrock's acceptance of employment with the company, in accordance with New York Stock Exchange Rule 303A.08. The company previously announced that Mr. Schuckenbrock has been appointed President and Chief Executive Officer and a member of the company's Board of Directors, effective April 3, 2013.

The stock option is for the purchase of 2,903,801 shares of the company's common stock, with an exercise price of $9.56, which was the closing price of the company's common stock reported on the New York Stock Exchange on April 3, 2013. The stock option will vest and become exercisable on a ratable monthly basis over 48 months based on continued service to the company, subject to acceleration in specified circumstances.

Accretive Health is providing the above information regarding Mr. Schuckenbrock's inducement grant in accordance with New York Stock Exchange Rule 303A.08.

About Accretive Health

At Accretive Health, our mission is to help our healthcare clients strengthen their financial stability and deliver better care at a more affordable cost to the communities they serve (increasing healthcare access to all). For more information, visit www.accretivehealth.com.

Accretive Health, Inc.
Investor Relations:
Atif Rahim
Telephone: 312.324.5476
email: [email protected]
or
Media:
Puneet Singh
Telephone: 330.565.6802
email: [email protected]


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACCRETIVE HEALTH, INC.
05/10 R1 RCM : Ascension Expands Revenue Cycle Management Agreement with R1 RCM
05/09 R1 RCM INC. : Entry into a Material Definitive Agreement (form 8-K)
05/09 R1 RCM INC. : Results of Operations and Financial Condition, Financial Statement..
05/09 R1 RCM : Management's Discussion and Analysis of Financial Condition and Results..
05/09 R1 RCM INC. (OTCMKTS : ACHI) Files An 8-K Results of Operations and Financial Co..
05/09 R1 RCM INC. (OTCMKTS : ACHI) Files An 8-K Entry into a Material Definitive Agree..
04/17 R1 RCM : Access Healthcare Welcomes Scott Schrader as Chief Commercial Officer
03/23 R1 RCM to Present at the 16th Annual Needham Healthcare Conference
2014 ACCRETIVE HEALTH, INC. : Accretive Health Provides Restatement Update
2014 ACCRETIVE HEALTH, INC. : Patrick Funck Joins Accretive Health as Chief Informati..
More news
Sector news : Ambulance & Emergency Services
12:20p FTSE edge up helped by M&S but miners weigh
11:18a Middle East rules hurts South Africa's Mediclinic earnings
05/19DJIHH HEALTHCARE BHD : Malaysia's IHH Healthcare 1Q Net Profit Rises
05/03DJFRESENIUS : Sales, Profit Increased in 1st Quarter -- Update
05/03DJFRESENIUS : Sales, Profit Increased in 1st Quarter
More sector news : Ambulance & Emergency Services
Advertisement
Financials ($)
Sales 2017 421 M
EBIT 2017 -15,1 M
Net income 2017 -28,6 M
Finance 2017 15,9 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 0,81x
EV / Sales 2018 0,58x
Capitalization 358 M
More Financials
Chart ACCRETIVE HEALTH, INC.
Duration : Period :
Accretive Health, Inc. Technical Analysis Chart | US00438V1035 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 3
Average target price 4,85 $
Spread / Average Target 42%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Gerard Flanagan President, Chief Executive Officer & Director
Steve J. Shulman Chairman
Christopher Simon Ricaurte Chief Financial Officer & Treasurer
Alex J. Mandl Independent Director
Charles J. Ditkoff Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACCRETIVE HEALTH, INC.-12.68%358
FRESENIUS SE & CO KGAA2.09%47 301
HCA HEALTHCARE INC10.69%30 204
FRESENIUS MEDICAL CARE..1.99%28 331
QUEST DIAGNOSTICS INC15.94%14 579
LABORATORY CORP. OF AM..9.28%14 371
More Results